{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:55:10Z","timestamp":1780520110046,"version":"3.54.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"suppl_1","funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["1U2RGH001913-01"],"award-info":[{"award-number":["1U2RGH001913-01"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"DOI":"10.1093\/infdis\/jix128","type":"journal-article","created":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T16:16:57Z","timestamp":1489421817000},"page":"S168-S175","source":"Crossref","is-referenced-by-count":24,"title":["Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes"],"prefix":"10.1093","volume":"216","author":[{"given":"Kimberly M.","family":"Thompson","sequence":"first","affiliation":[{"name":"Kid Risk, Inc, and"},{"name":"University of Central Florida, College of Medicine, Orlando"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radboud J.","family":"Duintjer Tebbens","sequence":"additional","affiliation":[{"name":"Kid Risk, Inc, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,1]]},"reference":[{"key":"key\n\t\t\t\t20180306121529_CIT0001","volume-title":"Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1)","author":"World Health Assembly","year":"2008"},{"key":"key\n\t\t\t\t20180306121529_CIT0002","volume-title":"Global synchronisation and the switch","author":"Global Polio Eradication Initiative"},{"key":"key\n\t\t\t\t20180306121529_CIT0003","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1586\/erv.11.195","article-title":"Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation","volume":"11","author":"Thompson","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"key\n\t\t\t\t20180306121529_CIT0004","first-page":"204","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, April 2012\u2014conclusions and recommendations, Polio eradication","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"key\n\t\t\t\t20180306121529_CIT0005","volume-title":"SAGE confirms global polio vaccine switch date as April 2016","author":"World Health Organization"},{"key":"key\n\t\t\t\t20180306121529_CIT0006","volume-title":"Global Polio Eradication Initiative\u2014circulating vaccine-derived poliovirus","author":"World Health Organization"},{"key":"key\n\t\t\t\t20180306121529_CIT0007","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/risa.12044","article-title":"Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal"},{"key":"key\n\t\t\t\t20180306121529_CIT0008","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/risa.12022","article-title":"Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs)","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal"},{"key":"key\n\t\t\t\t20180306121529_CIT0009","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1093\/infdis\/jit845","article-title":"Modeling the dynamics of oral poliovirus vaccine cessation","volume":"210","author":"Thompson","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0010","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1093\/infdis\/jit838","article-title":"Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation","volume":"210","author":"Duintjer Tebbens","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0011","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1539-6924.2006.00827.x","article-title":"Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication","volume":"26","author":"Tebbens","year":"2006","journal-title":"Risk Anal"},{"key":"key\n\t\t\t\t20180306121529_CIT0012","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12879-015-1115-5","article-title":"Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0013","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12879-015-1112-8","article-title":"An economic analysis of poliovirus risk management policy options for 2013\u20132052","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0014","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12879-015-0791-5","article-title":"Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination","volume":"15","author":"Kalkowska","year":"2015","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0015","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12879-015-1116-4","article-title":"The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission","volume":"15","author":"Thompson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0016","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s12879-015-1114-6","article-title":"Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0017","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12879-015-1116-4","article-title":"The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission","volume":"15","author":"Thompson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0018","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12879-016-1465-7","article-title":"Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0019","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12879-016-1536-9","article-title":"Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12879-016-1537-8","article-title":"Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0021","first-page":"340","article-title":"Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation","volume":"7","author":"Duintjer Tebbens","year":"2016","journal-title":"J Vaccines Vaccin"},{"key":"key\n\t\t\t\t20180306121529_CIT0022","doi-asserted-by":"crossref","first-page":"pii:20586","DOI":"10.2807\/1560-7917.ES2013.18.38.20586","article-title":"Insidious reintroduction of wild poliovirus into Israel, 2013","volume":"18","author":"Anis","year":"2013","journal-title":"Euro Surveill"},{"key":"key\n\t\t\t\t20180306121529_CIT0023","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14760584.2014.864563","article-title":"National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication","volume":"13","author":"Thompson","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"key\n\t\t\t\t20180306121529_CIT0024","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4172\/2157-7560.1000339","article-title":"Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk management","volume":"7","author":"Duintjer Tebbens","year":"2016","journal-title":"J Vaccines Vaccin"},{"key":"key\n\t\t\t\t20180306121529_CIT0025","first-page":"221","article-title":"Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies","volume":"72","author":"Mas Lago","year":"1994","journal-title":"Bull World Health Organ"},{"key":"key\n\t\t\t\t20180306121529_CIT0026","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ije\/30.5.1029","article-title":"Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication","volume":"30","author":"M\u00e1s Lago","year":"2001","journal-title":"Int J Epidemiol"},{"key":"key\n\t\t\t\t20180306121529_CIT0027","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/ije\/dyg185","article-title":"Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba","volume":"32","author":"M\u00e1s Lago","year":"2003","journal-title":"Int J Epidemiol"},{"key":"key\n\t\t\t\t20180306121529_CIT0028","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(05)66386-6","article-title":"Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand","volume":"366","author":"Huang","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180306121529_CIT0029","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1093\/infdis\/jit845","article-title":"Modeling the dynamics of oral poliovirus vaccine cessation","volume":"210","author":"Thompson","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0030","doi-asserted-by":"crossref","first-page":"e0130123","DOI":"10.1371\/journal.pone.0130123","article-title":"Combinations of quality and frequency of immunization activities to stop and prevent poliovirus transmission in the high-risk area of northwest Nigeria","volume":"10","author":"Duintjer Tebbens","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180306121529_CIT0031","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12879-016-1536-9","article-title":"Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0032","doi-asserted-by":"crossref","DOI":"10.3201\/eid2302.161210","article-title":"Estimated effect of inactivated poliovirus vaccine campaigns, Nigeria and Pakistan, January 2014\u2013April 2016","volume":"23","author":"Shirreff","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0033","article-title":"Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use","author":"Duintjer Tebbens","year":"2017;","journal-title":"Med Decis Making Policy Prac"},{"key":"key\n\t\t\t\t20180306121529_CIT0034","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12879-016-1537-8","article-title":"Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180306121529_CIT0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1017\/S0950268816002302","article-title":"Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy","volume":"145","author":"Duintjer Tebbens","year":"2017","journal-title":"Epidemiol Infect"},{"key":"key\n\t\t\t\t20180306121529_CIT0036","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2217\/fmb-2016-0126","article-title":"The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management","volume":"11","author":"Duintjer Tebbens","year":"2016","journal-title":"Future Microbiol"},{"key":"key\n\t\t\t\t20180306121529_CIT0037","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2334-14-45","article-title":"The potential impact of expanding target age groups for polio immunization campaigns","volume":"14","author":"Duintjer Tebbens","year":"2014","journal-title":"BMC Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/216\/suppl_1\/S168\/24265070\/jix128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T12:16:06Z","timestamp":1520338566000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/216\/suppl_1\/S168\/3935076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":37,"journal-issue":{"issue":"suppl_1","published-online":{"date-parts":[[2017,7,1]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix128","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7,1]]},"published":{"date-parts":[[2017,7,1]]}}}